LifeSci Capital analyst Charles Zhu downgraded Merus (MRUS) to Market Perform from Outperform with a $97 price target after the company agreed to be acquired by Genmab (GMAB) is an all-cash transaction valued at $8.0B, or $97 per share
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- Balanced Hold Rating on Genmab’s Acquisition of Merus Amid Valuation and Strategic Fit Concerns
- Merus downgraded to Neutral from Buy at Guggenheim
- Hold Rating Given to Merus Amid Genmab Acquisition Reflecting Full Stock Valuation and Strategic Asset Integration
- Merus downgraded to Neutral from Buy at H.C. Wainwright
- Genmab price target raised to $34 from $32 at Leerink